In an exchange filing made after market hours on Wednesday (May 3), the drug maker said: "AstraZeneca Pharma India has received a permission in Form CT-20 to import for sale and distribution of Trastuzumab deruxtecan (Enhertu) 100mg/5mL vial lyophilized powder for concentrate for solution for infusion from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.”

Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

The company stated that the receipt of this permission paves way for the launch of trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India for the specified indication, subject to the receipt of related statutory approvals, if any.

AstraZeneca Pharma India is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

The company reported 156.57% jump in net profit to Rs 29.30 crore 24.57% increase in sales to Rs 249.81 crore in Q3 FY23 over Q3 FY22.

The scrip advanced 0.76% to currently trade at Rs 3188 on the BSE.